RxDoctor Payments Data

Sorana Pop

Family · Phoenix, AZNPI 1164802690

Payments from drug & device makers

$8,148in general payments, 2019–2025

Across 466 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$842
  • GSK$695
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$454
  • Novo Nordisk$404
  • Pfizer$354
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$8,141100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,148 in reported general payments places this provider in the 95th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$64,832
Medicare patients
193
Services billed
1,051

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin44$72,601
OzempicSemaglutide51$68,307
EliquisApixaban38$41,360
JanuviaSitagliptin Phosphate19$29,536
TrulicityDulaglutide27$29,089
MyrbetriqMirabegron32$28,309
LinzessLinaclotide26$25,931
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$25,630
Breztri AerosphereBudesonide/Glycopyr/Formoterol30$20,136
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$15,838
FarxigaDapagliflozin Propanediol13$15,106
TradjentaLinagliptin15$12,812
Advair HfaFluticasone Propion/Salmeterol20$9,017
Spiriva HandihalerTiotropium Bromide12$5,981
SymbicortBudesonide/Formoterol Fumarate14$5,358

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$348$85,41359 claims
Novo NordiskOzempic$404$68,30751 claims
PfizerEliquis$354$41,36038 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$842$40,59957 claims
MerckJanuvia$76$29,53619 claims
Lilly USA, LLCTrulicity$224$29,08927 claims
AbbVieLinzess, Synthroid$1,618$28,39256 claims
Astellas Pharma US IncMyrbetriq$181$28,30932 claims
GSKTrelegy Ellipta$695$25,63022 claims
Sanofi-aventis U.S. LLCLantus$41$2,41013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,119 family providers in Arizona.

Other family in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →